Fig. 2: H3-nanovax encapsulating IAV proteins induce lung-resident B cell responses. | npj Vaccines

Fig. 2: H3-nanovax encapsulating IAV proteins induce lung-resident B cell responses.

From: Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection

Fig. 2

C57BL/6 mice were vaccinated i.n. with 500 μg of H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), NA/M1 (Purple), or left unvaccinated (naïve). Representative flow plots of total CD45i.v.Ab-CD19+ B cells (a) and Fas+ (CD45i.vAb-CD19+Fas+) B cells (b) within the lungs. At 45 days post-vaccination, lung-resident (i.e., CD45i.v.Ab-) B cells (c) and Fas+ B cells (d) were enumerated. Error bars, mean ± s.e.m. Data representative of two (c, d; M1/NA: n = 3–4 mice/group) or three (c, d); Naïve, HA/NP, and (NA/NP: n = 4–5 mice/group) independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test).

Back to article page